Letter/Communication
Guillain–Barré Syndrome
The New England journal of medicine, v 367(10), pp 974-974
06 Sep 2012
PMID: 22931279
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Although Yuki and Hartung mention that toxic neuropathy should be included in the differential diagnosis of the Guillain–Barré syndrome, they do not discuss the particular toxicities that should be considered. Specifically, arsenic neurotoxicity, often characterized by an ascending, symmetrical, sensorimotor neuropathy, strongly resembles the Guillain–Barré syndrome and should be specifically ruled out in all applicable cases. The best specimen to test for recent arsenic exposure is a 24-hour urine collection (in a metal-free container) for arsenic and creatinine. Measuring both arsenic and creatinine allows for more accurate determination of arsenic excretion. It is important to remember that arsenic testing can be confounded by certain dietary sources (especially seafood eaten within a week of testing). When test results are in doubt, clinicians should request speciation of arsenic (i.e., analysis of organoarsenicals and inorganic species, rather than total arsenic).
Metrics
Details
- Title
- Guillain–Barré Syndrome
- Creators
- Michael I. Greenberg - Drexel UniversityDavid Vearrier - Drexel University
- Publication Details
- The New England journal of medicine, v 367(10), pp 974-974
- Publisher
- Massachusetts Medical Soc
- Number of pages
- 1
- Resource Type
- Letter/Communication
- Language
- English
- Academic Unit
- College of Medicine; Emergency Medicine
- Web of Science ID
- WOS:000308343300032
- Scopus ID
- 2-s2.0-84865698208
- Other Identifier
- 991019312332904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Toxicology